Results 291 to 300 of about 174,356 (352)

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

From MAiD Referral to Targeted Therapy Success: A Case of <i>BRAF</i>-Mutated Anaplastic Thyroid Cancer. [PDF]

Reports (MDPI)
Stubbert B, Stewart P, Winquist E, Cecchini M, Browne C.   +4 more
europepmc   +1 more source

AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for WHO CNS5 adult‐type diffuse gliomas

Brain Pathology, Volume 36, Issue 2, March 2026.
ADAPTR recommendations for Adult‐type Diffuse Gliomas in Resource‐restrained settings. Abstract The fifth edition of the WHO classification of CNS Tumors (WHO CNS5) has revised the diagnostic and grading criteria for Adult‐type Diffuse Gliomas (ADGs) by integrating molecular parameters with histologic features.
Vani Santosh, Chitra Sarkar, Shilpa Rao, Ho‐Keung Ng, Junji Shibahara, Maysa Al‐Hussaini, Michael E. Buckland, Sung‐Hye Park, Tarik Tihan, Pieter Wesseling, David N. Louis, Takashi Komori   +11 more
wiley   +1 more source

Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations. [PDF]

Cancer Med
Effiom D, Aprati T, Karneris A, Lawless A, Sharova T, Johnson R, Menzies A, Long G, Park B, Jung S, Johnson D, Liu D, Bai X, Flaherty K, Sullivan R, Boland GM, Cohen S.   +16 more
europepmc   +1 more source

Predictive analysis of <i>BRAF</i> V600E mutation and central lymph node metastasis in papillary thyroid carcinoma. [PDF]

Oncol Lett
Peng J, Wu Z, Huang Y, Pan R, Fu Z, Wang J.   +5 more
europepmc   +1 more source

SPACA6-hosted miR-99b~125a~let-7e cluster shapes melanoma resistance by modulating mTOR-mediated immunosuppression. [PDF]

Front Immunol
Vallacchi V, Lupoli G, Shahaj E, Aloisi M, Bergamini S, Frigerio S, De Cecco L, Vergani B, Todoerti K, Banfi C, Leone BE, Di Guardo L, Gallino G, Cossa M, Valeri B, Rivoltini L, Huber V, Rodolfo M, Vergani E.   +18 more
europepmc   +1 more source

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i>^<i>V600E</i> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. [PDF]

JCO Precis Oncol
Salama AKS, Wang V, Macrae ER, Park JI, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.   +18 more
europepmc   +1 more source

Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer. [PDF]

Int J Mol Sci
Ochman B, Limanówka P, Mielcarska S, Kula A, Dawidowicz M, Hudy D, Szrot M, Piecuch J, Czuba Z, Waniczek D, Świętochowska E.   +10 more
europepmc   +1 more source

Targeted therapy in advanced <i>BRAF</i>-mutated colorectal cancer: systematic review and network meta-analysis.

BMJ
Qin BD, Jiao XD, Wang Z, Liu K, Ling Y, Wu Y, Zang YS.   +6 more
europepmc   +1 more source